Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CDC7 | O00311 | 8/20 | 0.43 |
| ▸ | DBF4 | Q9UBU7 | 8/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL954881 | 0.91 | SMN1; SMN2 (0.39) | LMNACDC7DBF4TRPM8ALDH1A1 | |
| SCHEMBL952001 | 0.90 | CDC7 (0.37) | LMNACDC7DBF4TRPM8ALDH1A1 | |
| SCHEMBL953769 | 0.87 | CDC7 (0.59) | LMNACDC7DBF4TRPM8ALDH1A1 | |
| SCHEMBL951974 | 0.85 | TRPM8 (0.41) | LMNACDC7DBF4TRPM8ALDH1A1 | |
| SCHEMBL957422 | 0.84 | CDC7 (0.59) | CDC7DBF4TRPM8ALDH1A1HPGD | |
| SCHEMBL952070 | 0.84 | CDC7 (0.47) | LMNACDC7DBF4TRPM8ALDH1A1 | |
| SCHEMBL953720 | 0.82 | TRPM8 (0.40) | LMNACDC7DBF4TRPM8ALDH1A1 | |
| SCHEMBL952918 | 0.81 | BLM (0.36) | LMNACDC7DBF4TRPM8ALDH1A1 | |
| SCHEMBL953687 | 0.81 | CDC7 (0.61) | LMNACDC7DBF4TRPM8ALDH1A1 | |
| SCHEMBL953635 | 0.81 | CDC7 (0.47) | LMNACDC7DBF4TRPM8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139589-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9090601-B2 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2391619-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20110003807-A1 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003806-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| WO-2010090716-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003807-A1 | Thiazole derivatives | MTOR, RICTOR, AKT2 | LMNA 4454/4885CDC7 601/4885DBF4 3288/4885 |
| US-20110003806-A1 | Heteroaryls and uses thereof | RICTOR, MTOR, AKT1S1 | LMNA 2019/4885CDC7 1063/4885DBF4 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.